Page 138 - 2021_09-Haematologica-web

J. Duell et al.
Acknowledgments
The authors would like to thank the patients and their families, clinical researchers, and their teams and hospitals that participated in this study. The authors thank Günter Fingerle-Rowson and
Emanuel Lohrmann of MorphoSys AG for their input to this man- uscript. This study was sponsored by MorphoSys AG. Medical writing assistance was provided by Rebecca Hurst, PhD of Syneos Health and funded by MorphoSys AG.
References
1. World Health Organization. World Cancer Report 2020: Cancer Research for Cancer Prevention. Cancer Control. 2020;199.
2.Sarkozy C, Sehn LH. New drugs for the management of relapsed or refractory dif- fuse large B-cell lymphoma. Ann Lymphoma. 2019;3:10.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: B-Cell Lymphomas V3.2021. Published 2021. https://www.nccn.org/professionals/physi- cian_gls/pdf/b-cell.pdf. Accessed February 7, 2021.
4. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diag- nosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116-v125.
5.Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
6.Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refrac- tory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56.
7. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refrac- tory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155-165.
8. Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed
or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, sin- gle-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988.
9. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579- 586.
10. Woyach JA, Awan F, Flinn IW, et al. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014;124(24):3553-3560.
11. Jurczak W, Zinzani PL, Hess G, et al. A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc- optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non- Hodgkin’s lymphoma: long-term follow- up, final analysis. Blood. 2019;134 (Suppl_1):4078.
12. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Published 2020. https://clinicalinfo.hiv.gov/sites/default/file s/guidelines/documents/Adult_OI.pdf. Accessed July 21, 2020.
13. US Food & Drug Administration. FDA grants accelerated approval to tafasitamab- cxix for diffuse large B-cell lymphoma. Published online 2020:1-2. https://www.fda.gov/drugs/drug-
approvals-and-databases/fda-grants-accel- erated-approval-tafasitamab-cxix-diffuse- large-b-cell-lymphoma. Accessed February 7, 2021.
14. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non- Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987-994.
15. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lym- phoma. Ann Oncol. 2011;22(7):1622-1627.
16. Zinzani PL, Rigacci L, Cox MC, et al. Lenalidomide monotherapy in heavily pre- treated patients with non-Hodgkin lym- phoma: an Italian observational multicenter retrospective study in daily clinical practice. Leuk Lymphoma. 2015;56(6):1671-1676.
17.Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candi- dates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98(11):1726-1731.
18. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabta- gene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multi- centre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31-42.
2426
haematologica | 2021; 106(9)